Increasing evidence suggests that selective activation or modulation of TNFR2 could offer therapeutic benefits in inflammatory diseases, including IBD, by promoting mucosal healing while minimizing systemic immunosuppression [13]. This evidence concerns the gene TNFRSF1B and inflammatory bowel disease.